Concepedia

R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin†

Paul J. Pockros, David R. Nelson, Eliot Godofsky, M. Rodríguez‐Torres, Gregory T. Everson, Michael Fried, Reem Ghalib, Stephen A. Harrison, Lisa M. Nyberg, Mitchell L. Shiffman,

Hepatology · 2008 · 101 citations · 15 references

DOIFull text

Open access

Abstract

A synergistic antiviral effect was observed when R1626 was combined with peginterferon alfa-2a +/- ribavirin; up to 74% of patients had undetectable HCV RNA at week 4. Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway.

References

15

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy et al. · New England Journal of Medicine · 2002 · 6.4K citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Michael P. Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet · 2001 · 6K citations

, , +7

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

Francesca J. Torriani, M. Rodríguez‐Torres, Jürgen K. Rockstroh et al. · New England Journal of Medicine · 2004 · 1.2K citations · Full text

Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons

Raymond T. Chung, Janet Andersen, Paul A. Volberding et al. · New England Journal of Medicine · 2004 · 873 citations · Full text

Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

Tara L. Kieffer, Christoph Sarrazin, Janice S. Miller et al. · Hepatology · 2007 · 378 citations